Effects of divided doses of steroids on side effects, cytokines, and activation of complement and granulocytes, coagulation and fibrinolysis after OKT3.
Bemelman
F J
FJ
Renal Transplant Unit, Academic Medical Centre, Amsterdam, The Netherlands.
Buysmann
S
S
Wilmink
J M
JM
Surachno
S
S
Hack
C E
CE
Schellekens
P T
PT
ten Berge
R J
RJ
D000933:Antifibrinolytic Agents; D000990:Antithrombin III / Q000032:analysis; D001777:Blood Coagulation; D003167:Complement Activation; D016572:Cyclosporine / Q000627:therapeutic use; D016207:Cytokines / Q000097:blood*; D004359:Drug Therapy, Combination; D005341:Fibrinolysin / Q000032:analysis; D005342:Fibrinolysis; D006084:Graft Rejection / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D015850:Interleukin-6 / Q000097:blood; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology; D010196:Pancreatic Elastase / Q000097:blood; D010447:Peptide Hydrolases / Q000032:analysis; D011239:Prednisolone / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D000979:alpha-2-Antiplasmin / Q000032:analysis
D000933:Antifibrinolytic Agents; D016207:Cytokines; D015850:Interleukin-6; D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C037742:plasmin-plasmin inhibitor complex; D016572:Cyclosporine; D000990:Antithrombin III; D011239:Prednisolone; D010447:Peptide Hydrolases; D010196:Pancreatic Elastase; D005341:Fibrinolysin